SCHEMBL4767650

SCHEMBL4767650

CCCCS(=O)(=O)N(Cc1cccc(Cl)c1Cl)c1ccc(C(=O)OC)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.49
MAPT P10636 6/20 0.46
LMNA P02545 3/20 0.46
SMN1; SMN2 Q16637 4/20 0.40
TSHR P16473 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
RAB9A P51151 4/20 0.40
ALDH1A1 P00352 5/20 0.38
GAA P10253 3/20 0.37
KDM4E B2RXH2 3/20 0.36
HTT P42858 1/20 0.36
POLB P06746 2/20 0.36
NPC1 O15118 2/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CASP1 P29466 1/20 0.35
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4774852 0.94 MAPT (0.47) L3MBTL1MAPTLMNASMN1; SMN2TSHR
SCHEMBL4768135 0.92 MAPT (0.49) L3MBTL1MAPTLMNASMN1; SMN2TSHR
SCHEMBL4775186 0.90 MAPT (0.46) L3MBTL1MAPTLMNASMN1; SMN2TSHR
SCHEMBL4777409 0.85 ALDH1A1 (0.51) L3MBTL1MAPTLMNASMN1; SMN2TSHR
SCHEMBL4777497 0.84 MAPT (0.49) L3MBTL1MAPTLMNASMN1; SMN2TSHR
SCHEMBL4776669 0.83 MAPT (0.46) L3MBTL1MAPTLMNASMN1; SMN2TSHR
SCHEMBL4775212 0.83 MAPT (0.48) L3MBTL1MAPTLMNASMN1; SMN2TSHR
SCHEMBL4776409 0.83 MAPT (0.48) L3MBTL1MAPTLMNASMN1; SMN2TSHR
SCHEMBL4773537 0.83 MAPT (0.51) L3MBTL1MAPTLMNASMN1; SMN2TSHR
SCHEMBL4767972 0.82 MAPT (0.48) L3MBTL1MAPTLMNASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 L3MBTL1 2781/4885MAPT 294/4885LMNA 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.